| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
2cureX AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.44 |
| 52 Week High | kr7.50 |
| 52 Week Low | kr0.29 |
| Beta | 0.68 |
| 1 Month Change | 4.52% |
| 3 Month Change | -80.58% |
| 1 Year Change | -93.73% |
| 3 Year Change | -97.80% |
| 5 Year Change | -97.54% |
| Change since IPO | -94.55% |
Recent News & Updates
Recent updates
We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate
Jun 03
2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans
Jan 06We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate
Sep 23We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow
Jun 02Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return
Feb 18How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?
Nov 29
Shareholder Returns
| 2CUREX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.8% |
| 1Y | -93.7% | -9.0% | 10.7% |
Return vs Industry: 2CUREX underperformed the Swedish Medical Equipment industry which returned -9% over the past year.
Return vs Market: 2CUREX underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| 2CUREX volatility | |
|---|---|
| 2CUREX Average Weekly Movement | 23.7% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: 2CUREX's share price has been volatile over the past 3 months.
Volatility Over Time: 2CUREX's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 14 | Kenneth Johansen | www.2curex.com |
2cureX AB (publ) operates as a medtech company in Europe. The company’s principal product is IndiTreat, an IVD test, which helps to predict cancer patient’s response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers.
2cureX AB (publ) Fundamentals Summary
| 2CUREX fundamental statistics | |
|---|---|
| Market cap | kr7.73m |
| Earnings (TTM) | -kr30.82m |
| Revenue (TTM) | kr2.95m |
2.6x
P/S Ratio-0.3x
P/E RatioIs 2CUREX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2CUREX income statement (TTM) | |
|---|---|
| Revenue | kr2.95m |
| Cost of Revenue | kr10.83m |
| Gross Profit | -kr7.89m |
| Other Expenses | kr22.93m |
| Earnings | -kr30.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -1.75 |
| Gross Margin | -267.63% |
| Net Profit Margin | -1,045.78% |
| Debt/Equity Ratio | 0% |
How did 2CUREX perform over the long term?
See historical performance and comparison